DOTmed January 10, 2024
Boston Scientific has agreed to purchase Axonics, Inc., a major player in the development of innovative devices for urinary and bowel dysfunction treatments, in a $3.7 billion deal poised to significantly bolster Boston Scientific’s urology portfolio.
The deal comes as a response to the growing need for effective treatments for overactive bladder (OAB) and fecal incontinence, conditions that affect nearly 30 million adults aged 40 and older in the United States, with serious implications for their quality of life and mental health.
This move also marks Boston Scientific’s entry into the high-growth area of sacral neuromodulation therapy, a minimally invasive treatment for OAB and fecal incontinence. This therapy involves delivering mild electrical pulses to the sacral nerve, thereby improving bladder...
Today's Sponsors
Today's Sponsor